Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes

Journal of Pathology

Volumn 246, Issue 2, 2018, Pages 217-230

  Genser, Laurent ^a,b   Aguanno, Doriane ^a   Soula, Hédi A ^a   Dong, Liping ^a   Trystram, Laurence ^b   Assmann, Karen ^a   Salem, Joe Elie ^b   Vaillant, Jean Christophe ^b   Oppert, Jean Michel ^b   Laugerette, Fabienne ^c   Michalski, Marie Caroline ^c   Wind, Philippe ^d   Rousset, Monique ^a   Brot Laroche, Edith ^a   Leturque, Armelle ^a   Clément, Karine ^a,b   Thenet, Sophie ^a   Poitou, Christine ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

^d AVICENNE HOSPITAL   (France)

Author keywords

inflammation; intestinal barrier function; intestinal permeability; jejunum; lipids; obesity; tight junction proteins; type 2 diabetes; Ussing chamber

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIPOPOLYSACCHARIDE BINDING PROTEIN; METFORMIN; OCCLUDIN; PROTEIN ZO1; TRIACYLGLYCEROL; TRICELLULIN; ACUTE PHASE PROTEIN; CARRIER PROTEIN; CHOLERA TOXIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MARVELD2 PROTEIN, HUMAN; MEMBRANE PROTEIN; OCLN PROTEIN, HUMAN; ZONULIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; ENTERITIS; EX VIVO STUDY; FAT INTAKE; FEMALE; HUMAN; INTESTINE MUCOSA PERMEABILITY; JEJUNAL PERMEABILITY; JEJUNUM; JEJUNUM EPITHELIUM; MACROMOLECULE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESE PATIENT; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TIGHT JUNCTION; BLOOD; CACO-2 CELL LINE; CASE CONTROL STUDY; COMPLICATION; DRUG EFFECT; INFLAMMATION; INTESTINE ABSORPTION; METABOLISM; MICELLE; MIDDLE AGED; PATHOPHYSIOLOGY; PERMEABILITY; YOUNG ADULT;

ACUTE-PHASE PROTEINS; ADULT; AGED; CACO-2 CELLS; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHOLERA TOXIN; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFLAMMATION; INTESTINAL ABSORPTION; JEJUNUM; LIPIDS; MALE; MARVEL DOMAIN CONTAINING 2 PROTEIN; MEMBRANE GLYCOPROTEINS; MICELLES; MIDDLE AGED; OBESITY; OCCLUDIN; PERMEABILITY; TIGHT JUNCTIONS; YOUNG ADULT;

EID: 85052829892     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.5134     Document Type: Article

References (56)

1. Odenwald MA, Turner JR. Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol 2013; 11: 1075–1083
2. Konig J, Wells J, Cani PD, et al. Human intestinal barrier function in health and disease. Clin Transl Gastroenterol 2016; 7: e196
3. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009; 9: 799–809
4. Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol 2017; 14: 9–21
5. Dalmas E, Rouault C, Abdennour M, et al. Variations in circulating inflammatory factors are related to changes in calorie and carbohydrate intakes early in the course of surgery-induced weight reduction. Am J Clin Nutr 2011; 94: 450–458
6. Calder PC, Ahluwalia N, Brouns F, et al. Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr 2011; 106(suppl 3): S5–S78
7. Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 2012; 56: 1751–1759
8. Dalmas E, Venteclef N, Caer C, et al. T cell-derived IL-22 amplifies IL-1β-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. Diabetes 2014; 63: 1966–1977
9. Grant RW, Dixit VD. Adipose tissue as an immunological organ. Obesity (Silver Spring) 2015; 23: 512–518
10. Monteiro-Sepulveda M, Touch S, Mendes-Sa C, et al. Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling. Cell Metab 2015; 22: 113–124
11. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470–1481
12. Araujo JR, Tomas J, Brenner C, et al. Impact of high-fat diet on the intestinal microbiota and small intestinal physiology before and after the onset of obesity. Biochimie 2017; 141: 97–106
13. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761–1772
14. Teixeira TF, Souza NC, Chiarello PG, et al. Intestinal permeability parameters in obese patients are correlated with metabolic syndrome risk factors. Clin Nutr 2012; 31: 735–740
15. Damms-Machado A, Louis S, Schnitzer A, et al. Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction. Am J Clin Nutr 2017; 105: 127–135
16. Brignardello J, Morales P, Diaz E, et al. Pilot study: alterations of intestinal microbiota in obese humans are not associated with colonic inflammation or disturbances of barrier function. Aliment Pharmacol Ther 2010; 32: 1307–1314
17. Basu S, Haghiac M, Surace P, et al. Pregravid obesity associates with increased maternal endotoxemia and metabolic inflammation. Obesity (Silver Spring) 2011; 19: 476–482
18. Vors C, Pineau G, Drai J, et al. Postprandial endotoxemia linked with chylomicrons and lipopolysaccharides handling in obese versus lean men: a lipid dose–effect trial. J Clin Endocrinol Metab 2015; 100: 3427–3435
19. Winer DA, Luck H, Tsai S, et al. The intestinal immune system in obesity and insulin resistance. Cell Metab 2016; 23: 413–426
20. Johnson AM, Costanzo A, Gareau MG, et al. High fat diet causes depletion of intestinal eosinophils associated with intestinal permeability. PLoS One 2015; 10: e0122195
21. Hamilton MK, Boudry G, Lemay DG, et al. Changes in intestinal barrier function and gut microbiota in high-fat diet-fed rats are dynamic and region dependent. Am J Physiol Gastrointest Liver Physiol 2015; 308: G840–G851
22. Tomas J, Mulet C, Saffarian A, et al. High-fat diet modifies the PPAR-gamma pathway leading to disruption of microbial and physiological ecosystem in murine small intestine. Proc Natl Acad Sci U S A 2016; 113: E5934–E5943
23. Ghoshal S, Witta J, Zhong J, et al. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009; 50: 90–97
24. Erridge C, Attina T, Spickett CM, et al. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 1286–1292
25. Laugerette F, Vors C, Geloen A, et al. Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J Nutr Biochem 2011; 22: 53–59
26. Watson CJ, Hoare CJ, Garrod DR, et al. Interferon-gamma selectively increases epithelial permeability to large molecules by activating different populations of paracellular pores. J Cell Sci 2005; 118: 5221–5230
27. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes Care 2015; 38(suppl 1): S8–S16
28. Ciangura C, Bouillot JL, Lloret-Linares C, et al. Dynamics of change in total and regional body composition after gastric bypass in obese patients. Obesity (Silver Spring) 2010; 18: 760–765
29. Chantret I, Rodolosse A, Barbat A, et al. Differential expression of sucrase–isomaltase in clones isolated from early and late passages of the cell line Caco-2: evidence for glucose-dependent negative regulation. J Cell Sci 1994; 107(Pt 1): 213–225
30. Menard S, Cerf-Bensussan N, Heyman M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal Immunol 2010; 3: 247–259
31. Chateau D, Pauquai T, Delers F, et al. Lipid micelles stimulate the secretion of triglyceride-enriched apolipoprotein B48-containing lipoproteins by Caco-2 cells. J Cell Physiol 2005; 202: 767–776
32. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005; 129: 550–564
33. Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 2007; 56: 61–72
34. Krug SM, Amasheh S, Richter JF, et al. Tricellulin forms a barrier to macromolecules in tricellular tight junctions without affecting ion permeability. Mol Biol Cell 2009; 20: 3713–3724
35. Al-Sadi R, Khatib K, Guo S, et al. Occludin regulates macromolecule flux across the intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 2011; 300: G1054–G1064
36. Brun P, Castagliuolo I, Di Leo V, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G518–G525
37. Suzuki T, Hara H. Dietary fat and bile juice, but not obesity, are responsible for the increase in small intestinal permeability induced through the suppression of tight junction protein expression in LETO and OLETF rats. Nutr Metab (Lond) 2010; 7: 19
38. Marchiando AM, Shen L, Graham WV, et al. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol 2010; 189: 111–126
39. Kojima T, Fuchimoto J, Yamaguchi H, et al. c-Jun N-terminal kinase is largely involved in the regulation of tricellular tight junctions via tricellulin in human pancreatic duct epithelial cells. J Cell Physiol 2010; 225: 720–733
40. Bucker R, Schulz E, Gunzel D, et al. α-Haemolysin of Escherichia coli in IBD: a potentiator of inflammatory activity in the colon. Gut 2014; 63: 1893–1901
41. Clarke LL. A guide to Ussing chamber studies of mouse intestine. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1151–G1166
42. Murakami Y, Tanabe S, Suzuki T. High-fat diet-induced intestinal hyperpermeability is associated with increased bile acids in the large intestine of mice. J Food Sci 2016; 81: H216–H222
43. Sarathy J, Detloff SJ, Ao M, et al. The Yin and Yang of bile acid action on tight junctions in a model colonic epithelium. Physiol Rep 2017; 5: e13294
44. Beaslas O, Cueille C, Delers F, et al. Sensing of dietary lipids by enterocytes: a new role for SR-BI/CLA-1. PLoS One 2009; 4: e4278
45. Benitez JM, Garcia-Sanchez V. Faecal calprotectin: management in inflammatory bowel disease. World J Gastrointest Pathophysiol 2015; 6: 203–209
46. Bischoff SC, Barbara G, Buurman W, et al. Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterol 2014; 14: 189
47. Thaiss CA, Levy M, Grosheva I, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science 2018; 359: 1376–1383
48. Chassaing B, Raja SM, Lewis JD, et al. Colonic microbiota encroachment correlates with dysglycemia in humans. Cell Mol Gastroenterol Hepatol 2017; 4: 205–221
49. Salles Teixeira TF, Boroni Moreira AP, Silva Souza NC, et al. Intestinal permeability measurements; general aspects and possible pitfalls. Nutr Hosp 2014; 29: 269–281
50. Savassi-Rocha AL, Diniz MT, Vilela EG, et al. Changes in intestinal permeability after Roux-en-Y gastric bypass. Obes Surg 2014; 24: 184–190
51. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev 2011; 91: 151–175
52. Moreno-Navarrete JM, Sabater M, Ortega F, et al. Circulating zonulin, a marker of intestinal permeability, is increased in association with obesity-associated insulin resistance. PLoS One 2012; 7: e37160
53. Moreno-Navarrete JM, Ortega F, Serino M, et al. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. Int J Obes (Lond) 2012; 36: 1442–1449
54. Mokkala K, Pellonpera O, Roytio H, et al. Increased intestinal permeability, measured by serum zonulin, is associated with metabolic risk markers in overweight pregnant women. Metabolism 2017; 69: 43–50
55. Wells JM, Brummer RJ, Derrien M, et al. Homeostasis of the gut barrier and potential biomarkers. Am J Physiol Gastrointest Liver Physiol 2017; 312: G171–G193
56. Petit CS, Barreau F, Besnier L, et al. Requirement of cellular prion protein for intestinal barrier function and mislocalization in patients with inflammatory bowel disease. Gastroenterology 2012; 143: 122–132.e15